Biofrontera Reports Q1 2026 Earnings with Revenue Growth and Regulatory Milestone
Biofrontera (BFRI) reported a revenue increase of $10.1 million for Q1 2026, driven by higher Ameluz unit volume and pricing adjustments. The company also achieved an FDA regulatory milestone as the sNDA for Ameluz in superficial basal cell carcinoma was accepted.
Topics: adjusted_ebitda fda_milestone gross_margin_improvement revenue_growth